CreatorsPublishersAdvertisers
View more in
Cancer

Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLC

onclive.com
 2021-09-10

Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer. Vilde D. Haakensen, MD, PhD, project...

www.onclive.com

Comments / 0

Comments / 0